Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study
Open Access
- 1 January 2018
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 12
Abstract
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common in patients with underlying moderate to severe COPD and are associated with increased health and economic burden. International and Chinese guidelines recommend using glucocorticoids for the management of AECOPD because glucocorticoid therapy has been shown to benefit clinical outcomes. However, only scant data are available for current status of glucocorticoid therapy in hospitalized AECOPD patients in China. The aim of the study was to identify current use of glucocorticoids for the treatment of AECOPD in China. This retrospective, multicenter, noninterventional study evaluated the treatment pattern of AECOPD in patients hospitalized from January 2014 to September 2014 at 43 sites (41 tertiary hospitals and two secondary hospitals) in China. The endpoints of the study were the percentage of patients receiving glucocorticoids by different routes of administration, doses and duration, mortality, and the mean length of hospitalization. A total of 4569 patients (90.17%) received glucocorticoids for AECOPD treatment. A combination of nebulized and systemic route was most frequently used (40.51%), followed by using nebulized route alone (38.00%), systemic route alone (15.45%), and inhaled route other than nebulization (6.04%). Furthermore, the most commonly prescribed glucocorticoids of the nebulized, intravenous, inhaled (other than nebulized) and oral route was budesonide (69.4%), methylprednisolone sodium succinate (45.31%), fluticasone propionate (19.54%), and prednisone acetate (11.90%), respectively. The in-hospital mortality rate was 1.24% and the mean length of hospitalization was 12.22 ± 6.20 days (± SD). Our study was the first study of the treatment pattern of glucocorticoids in the management of hospitalized AECOPD patients in China. Data indicates that there is a gap in the implementation of international guidelines for the treatment of AECOPD in China. Further studies are warranted to clarify the appropriate glucocorticoids strategy for the management of AECOPD to determine the optimal route of administration, dose and duration, and resulting clinical outcomes.Keywords
Funding Information
- AstraZeneca, Shanghai, China
This publication has 31 references indexed in Scilit:
- Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort studyBMJ Open, 2014
- Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of ChinaInternational Journal of Chronic Obstructive Pulmonary Disease, 2014
- COPD in ChinaChest, 2011
- Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2008
- The role of nebulised budesonide in the treatment of exacerbations of COPDEuropean Respiratory Journal, 2007
- Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax, 2005
- Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseClinical Drug Investigation, 2003
- Comparison of Nebulized Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled TrialAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trialThe Lancet, 1999
- Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man.1982